Thomas Perls和David J. Handelsman在2015年《美國老年病學會期刊(英語:Journal of the American Geriatrics Society)》的社論中認為,因為診斷本身不容易定義、藥廠推廣睾固酮和人類生長激素的宣傳及廣告,再加上營養補充品公司販售針對各種年長者的營養補充品,相關的症狀其實是過度診斷(英語:overdiagnosed)及過度醫療[99]。Perls和Handelsman指出,「美國睾固酮的銷量由2002年的3.24億美元到2012年的20億美元,睾固酮處方的數量由2007年的一億美元到2012年的五億美元,這些還不包括複合藥店、互聯網和直接銷售給病患的金額。」[99]
What causes menopause?. Eunice Kennedy Shriver National Institute of Child Health and Human Development. 6 May 2013 [8 March 2015]. (原始內容存檔於2015-04-02).
Krause, MS; Nakajima, ST. Hormonal and Nonhormonal Treatment of Vasomotor Symptoms.. Obstetrics and Gynecology Clinics of North America. March 2015, 42 (1): 163–179. PMID 25681847. doi:10.1016/j.ogc.2014.09.008.
What are the symptoms of menopause. Eunice Kennedy Shriver National Institute of Child Health and Human Development. 6 May 2013 [8 March 2015]. (原始內容存檔於2015-03-20).
What causes menopause?. Eunice Kennedy Shriver National Institute of Child Health and Human Development. 6 May 2013 [8 March 2015]. (原始內容存檔於2015-04-02).
Pérez-López, FR; Cuadros, JL; Fernández-Alonso, AM; Chedraui, P; Sánchez-Borrego, R; Monterrosa-Castro, A. Quality of life in a large cohort of mid-aged Colombian women assessed using the Cervantes Scale. Maturitas. 2012, 73 (4): 369–72. PMID 23041251. doi:10.1016/j.maturitas.2012.09.004.
Chedraui, P; Pérez-López, FR; Mendoza, M; Leimberg, ML; Martínez, MA; Vallarino, V; Hidalgo, L. Factors related to increased daytime sleepiness during the menopausal transition as evaluated by the Epworth sleepiness scale. Maturitas. 2010, 65 (1): 75–80. PMID 19945237. doi:10.1016/j.maturitas.2009.11.003.
Arakane, M; Castillo, C; Rosero, MF; Peñafiel, R; Pérez-López, FR; Chedraui, P. Factors relating to insomnia during the menopausal transition as evaluated by the Insomnia Severity Index.. Maturitas. 2011, 69 (2): 157–61. PMID 21444163. doi:10.1016/j.maturitas.2011.02.015.
Monterrosa-Castro, A; Marrugo-Flórez, M; Romero-Pérez, I; Chedraui, P; Fernández-Alonso, AM; Pérez-López, FR. Prevalence of insomnia and related factors in a large mid-aged female Colombian sample. Maturitas. 2013, 74 (4): 346–51. PMID 23391501. doi:10.1016/j.maturitas.2013.01.009.
Souza, Hugo. Autonomic Cardiovascular Damage during Post-menopause: the Role of Physical Training. Aging and Disease. 2013, 4 (6): 320–28. ISSN 2152-5250. doi:10.14336/AD.2013.0400320.
Muka, Taulant; Oliver-Williams, Clare; Kunutsor, Setor; Laven, Joop S. E.; Fauser, Bart C. J. M.; Chowdhury, Rajiv; Kavousi, Maryam; Franco, Oscar H. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality. JAMA Cardiology. 14 September 2016, 1: 767. doi:10.1001/jamacardio.2016.2415.
Monterrosa-Castro, A; Romero-Pérez, I; Marrugo-Flórez, M; Fernández-Alonso, AM; Chedraui, P; Pérez-López, FR. Quality of life in a large cohort of mid-aged Colombian women assessed using the Cervantes Scale. Menopause. 2012, 19 (8): 924–30. PMID 22549166. doi:10.1097/gme.0b013e318247908d.
McNamara, M; Batur, P; DeSapri, KT. In the clinic. Perimenopause.. Annals of Internal Medicine. 3 February 2015, 162 (3): ITC1–15. PMID 25643316. doi:10.7326/AITC201502030.
Bellipanni, G; Di Marzo, F; Blasi, F; Di Marzo, A. Effects of melatonin in perimenopausal and menopausal women: our personal experience. 2005. Annals of the New York Academy of Sciences. 2005-12, 1057 (1): 393–402. PMID 16399909. doi:10.1196/annals.1356.030.
Burger, HG. Diagnostic role of follicle stimulating hormone (FSH) measurements during menopausal transition – an analysis of FSH, oestradiol and inhibin. European Journal of Endocrinology. 1994, 130 (1): 38–42. PMID 8124478. doi:10.1530/eje.0.1300038.
Nahás E, Pontes A, Traiman P, NahásNeto J, Dalben I, De Luca L. Inhibin B and ovarian function after total abdominal hysterectomy in women of reproductive age. Gynecol. Endocrinol. 2003, 17: 125–31. PMID 12737673. doi:10.1080/713603218.
Burger, HG. Diagnostic role of follicle stimulating hormone (FSH) measurements during menopausal transition – an analysis of FSH, oestraiol and inhibin. European Journal of Endocrinology. 1994, 130 (1): 38–42. PMID 8124478. doi:10.1530/eje.0.1300038.
Simpson, ER; Davis, SR. Minireview: aromatase and the regulation of estrogen biosynthesis – some new perspectives. Endocrinology. 2001, 142 (11): 4589–94. PMID 11606422. doi:10.1210/en.142.11.4589.
Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause (New York, N.Y.). Mar 2010, 17 (2): 242–55. PMID 20154637. doi:10.1097/gme.0b013e3181d0f6b9.
The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. July 2017, 24 (7): 728–753. doi:10.1097/GME.0000000000000921.
de Villiers, TJ; Stevenson, JC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric. June 2012, 15 (3): 263–66. PMID 22612613. doi:10.3109/13697137.2012.659975.
Chlebowski, R. T.; Anderson, G. L. Menopausal hormone therapy and breast cancer mortality: clinical implications. Therapeutic Advances in Drug Safety. 2015, 6 (2): 45–56. ISSN 2042-0986. doi:10.1177/2042098614568300.
Bevers, TB. The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women. J Natl Compr Canc Netw. 2007, 5 (8): 817–22.
Orleans, RJ; Li, L; Kim, MJ; Guo, J; Sobhan, M; Soule, L; Joffe, HV. FDA approval of paroxetine for menopausal hot flushes. The New England Journal of Medicine. 2014, 370 (19): 1777–79. PMID 24806158. doi:10.1056/NEJMp1402080.
Nedrow, A; Miller, J; Walker, M; Nygren, P; Huffman, LH; Nelson, HD. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med. 2006, 166 (14): 1453–65. doi:10.1001/archinte.166.14.1453.
Bolaños, R; Del Castillo, A; Francia, J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis.. Menopause. 2010, 17 (3): 660–66. PMID 20464785. doi:10.1097/gme.0b013e3181cb4fb5.
EFSA Femarelle® and bone mineral density (頁面存檔備份,存於互聯網檔案館) Scientific substantiation of a health claim related to "Femarelle®" and "induces bone formation and increases bone mineral density reducing the risk for osteoporosis and other bone disorders" pursuant to Article 14 of the Regulation (EC) No 1924/20061 Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies. The EFSA Journal (2008) 785, pp. 1–10]
Leach, MJ; Moore, V. Black cohosh (Cimicifuga spp.) for menopausal symptoms.. Cochrane Database of Systematic Reviews. 12 September 2012, 9: CD007244. PMID 22972105. doi:10.1002/14651858.CD007244.pub2.
Clement, YN; Onakpoya, I; Hung, SK; Ernst, E. Effects of herbal and dietary supplements on cognition in menopause: a systematic review.. Maturitas. March 2011, 68 (3): 256–63. PMID 21237589. doi:10.1016/j.maturitas.2010.12.005.
Wells, GA; Cranney, A; Peterson, J; Boucher, M; Shea, B; Robinson, V; Coyle, D; Tugwell, P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. Jan 23, 2008, (1): CD001155. PMID 18253985. doi:10.1002/14651858.CD001155.pub2.
Winterich, J. (August 2008). "Gender, medicine, and the menopausal body: How biology and culture influence women's experiences with menopause". Paper presented at the annual meeting of the American Sociological Association, New York. Retrieved 11 November 2008 from Allacademic.com互聯網檔案館的存檔,存檔日期9 July 2012.
Lock, M. & Nguyen, V. (2010) An Anthropology of Biomedicine, Chapter 4 "Local Biologies and Human Difference" (pp. 84–89), West Sussex, Wiley-Blackwell
Gold, EB; Block, G; Crawford, S; Lachance, L; FitzGerald, G; Miracle, H; Sherman, S. Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health Across the Nation. American Journal of Epidemiology. 2004, 159 (12): 1189–99. PMID 15191936. doi:10.1093/aje/kwh168.